Osiris Therapeutics Inc. said Friday Canadian regulators requested additional information to support the company's request to approve the stem cell therapy Prochymal.
The therapy is aimed at treating graft vs. host disease, which is a side effect of organ or bone marrow transplants. Osiris is developing Prochymal through a partnership with Genzyme Corp. of Cambridge, Mass.
The regulatory body in Canada, called Health Canada, determined that the application is not in full compliance current regulations. The agency gave Osiris 90 days to respond to the questions.
The company said it intends to "expeditiously" provide the necessary information.
Shares of Osiris rose 26 cents, or 3.7 percent, to $7.32 in afternoon trading. The stock has traded between $5.39 and $9.24 over the last 52 weeks.